In yesterday’s Wall Street session, Hoth Therapeutics Inc. (NASDAQ:HOTH) shares traded at $6.56, down -15.90% from the previous session.
2 analysts cover Hoth Therapeutics Inc. (NASDAQ:HOTH), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $33.00 and a low of $5.00, we find $19.00. Given the previous closing price of $7.80, this indicates a potential upside of 143.59 percent. HOTH stock price is now 45.99% away from the 50-day moving average and -33.36% away from the 200-day moving average. The market capitalization of the company currently stands at $11.68M.
The stock has received a hold rating from 0 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $19.00 as their price target over the next twelve months.
With the price target of $10, The Benchmark Company recently initiated with Speculative Buy rating for Hoth Therapeutics Inc. (NASDAQ: HOTH).
In other news, Knie Robb, CEO and President bought 10,000 shares of the company’s stock on Sep 19. The stock was bought for $3,900 at an average price of $0.39. Upon completion of the transaction, the CEO and President now directly owns 828,259 shares in the company, valued at $5.43 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 16, CEO and President Knie Robb bought 10,000 shares of the business’s stock. A total of $4,000 was incurred on buying the stock at an average price of $0.40. This leaves the insider owning 818,259 shares of the company worth $5.37 million. A total of 2.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HOTH stock. A new stake in Hoth Therapeutics Inc. shares was purchased by TWO SIGMA SECURITIES, LLC during the first quarter worth $6,000. MILLENNIUM MANAGEMENT LLC invested $4,000 in shares of HOTH during the first quarter. In the first quarter, ROYAL BANK OF CANADA acquired a new stake in Hoth Therapeutics Inc. valued at approximately $2,000. In total, there are 17 active investors with 8.30% ownership of the company’s stock.
On Tuesday morning Hoth Therapeutics Inc. (NASDAQ: HOTH) stock kicked off with the opening price of $7.03. During the past 12 months, Hoth Therapeutics Inc. has had a low of $2.61 and a high of $43.75. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 9.40, and a quick ratio of 9.40. The fifty day moving average price for HOTH is $4.49 and a two-hundred day moving average price translates $9.84 for the stock.
The latest earnings results from Hoth Therapeutics Inc. (NASDAQ: HOTH) was released for Jun, 2022.
Hoth Therapeutics Inc.(HOTH) Company Profile
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.